PTC Therapeutics (PTCT) submitted the vatiquinone New Drug Application, or NDA, for the treatment of children and adults living with Friedreich ataxia, or FA, to the FDA. The vatiquinone NDA is ...

Shares of PTC Therapeutics PTCT rose nearly 19% on Monday after announcing that it has entered into an exclusive global licensing and collaboration agreement with pharma giant Novartis NVS for ...

Morgan Stanley has upgraded PTC Therapeutics (NASDAQ:PTCT), while downgrading Immuneering (NASDAQ:IMRX) and Amicus Therapeutics (NASDAQ:FOLD). The investment bank raised its rating on PTC (NASDAQ ...

PTC Therapeutics PTCT shares soared 16.5% in the last trading session to close at $40.77. The move was backed by solid volume with far more shares changing hands than in a normal session.

In a report released on December 2, Gena Wang from Barclays maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), with a price target of $56.00. The company’s shares opened ...